Priya Sriskandarajah/LinkedIn, Francesco Passamonti/policlinico.mi.it and Claire Harrison/LinkedIn
Jun 14, 2026, 18:00
Priya Sriskandarajah: Great Presentations on Recent Advances in Myelofibrosis at EHA 2026
Priya Sriskandarajah, Consultant Haematologist at Guy’s and St Thomas’ NHS Foundation Trust, shared a post on LinkedIn:
“Great oral presentations discussing recent results from INDEPENDENCE study with Luspatercept by Francesco Passamonti and exciting results from INCA033989 in MF patients with impressive response by Claire Harrison.”

Stay udpated with Hemostasis Today.
-
Nov 14, 2026, 10:00Benjamin Tur: Putting Iron Deficiency Anemia on the Global Agenda at the Paris Peace Forum’s Child Summit
-
Nov 14, 2026, 09:48Jack Shuang Hou: FDA Approves Bayer’s Sunharbo – First Factor XIa Inhibitor for Secondary Stroke Prevention
-
Nov 14, 2026, 09:42Samwel Mikaye: What Every Patient Should Know About DVT Symptoms and Treatment
-
Nov 14, 2026, 09:37Chronic Preoperative Corticosteroid Use and Postoperative Venous Thromboembolism Risk – Thrombosis and Haemostasis Journal
-
Nov 14, 2026, 09:30Ney Carter Borges: Vulnerable Plaque – Imaging and Clinical Significance
-
Nov 14, 2026, 09:25Carmelo Raffo: How Much Antithrombotic Therapy is Truly Necessary after LAAC?
-
Nov 14, 2026, 09:19Mary Cushman: Excellent to Have Jordan Shavit Visit Us for a Virtual Lab Meeting Today
-
Nov 14, 2026, 09:15Chancellor Donald: Heading to ASH 2026 in New Orleans? Let’s Connect on Faculty Opportunities at Tulane
-
Nov 14, 2026, 09:11Sajja Venkatesh: FDA Approved Asundexian, the First Factor XIa Inhibitor